Image

Breaking News

Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma”
02/05/2021

Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma

  March 11, 2021|  Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
01/26/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  January 24, 2021 19:07 ET | Source: Junshi Biosciences   Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma”
11/24/2020

Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma

Published: Nov 23, 2020 By Mark Terry in BIOSPACE Immunocore, based in Oxfordshire, England, Conshohocken, Pennsylvania and Rockville, Maryland, announced that its Phase…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “AIM at Melanoma Opens the Fourth Branch of Fresh Frozen Primary Tissue Bank at Robert H. Lurie Comprehensive Cancer Center of Northwestern University”
01/23/2020

AIM at Melanoma Opens the Fourth Branch of Fresh Frozen Primary Tissue Bank at Robert H. Lurie Comprehensive Cancer Center of Northwestern University

  January 23, 2020 (San Rafael, California)… AIM at Melanoma and AIM at Melanoma Research Foundation announce the opening of…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University”
11/14/2019

AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University

  AIM AT MELANOMA OPENS THIRD BRANCH OF FRESH FROZEN PRIMARY TISSUE BANK AT THE KNIGHT CANCER INSTITUTE AT OREGON…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center”
09/09/2019

AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center

September 9, 2019 (San Rafael, California) AIM at Melanoma announces the grand opening of the second branch of the International…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/05/2021

Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma

  March 11, 2021|  Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Featured image for “Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/26/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  January 24, 2021 19:07 ET | Source: Junshi Biosciences   Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/24/2020

Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma

Published: Nov 23, 2020 By Mark Terry in BIOSPACE Immunocore, based in Oxfordshire, England, Conshohocken, Pennsylvania and Rockville, Maryland, announced that its Phase…
Featured image for “Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/23/2020

AIM at Melanoma Opens the Fourth Branch of Fresh Frozen Primary Tissue Bank at Robert H. Lurie Comprehensive Cancer Center of Northwestern University

  January 23, 2020 (San Rafael, California)… AIM at Melanoma and AIM at Melanoma Research Foundation announce the opening of…
Featured image for “AIM at Melanoma Opens the Fourth Branch of Fresh Frozen Primary Tissue Bank at Robert H. Lurie Comprehensive Cancer Center of Northwestern University”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/14/2019

AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University

  AIM AT MELANOMA OPENS THIRD BRANCH OF FRESH FROZEN PRIMARY TISSUE BANK AT THE KNIGHT CANCER INSTITUTE AT OREGON…
Featured image for “AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/09/2019

AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center

September 9, 2019 (San Rafael, California) AIM at Melanoma announces the grand opening of the second branch of the International…
Featured image for “AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “Inheriting Cancer Risk Factors”
Feb. 21, 2025

Inheriting Cancer Risk Factors

Featured image for “The Heart of Care: Palliative Care and Oncology Social Work”
Feb. 17, 2025

The Heart of Care: Palliative Care and Oncology Social Work

Featured image for “Men and Women and Melanoma: Who’s Winning the Battle?”
Feb. 14, 2025

Men and Women and Melanoma: Who’s Winning the Battle?

Featured image for “Genetic Testing Performed in Melanoma”
Feb. 06, 2025

Genetic Testing Performed in Melanoma

Featured image for “Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma”
Jan. 21, 2025

Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma

Filter by Tag